Jeffrey Settleman

40.2k total citations · 9 hit papers
158 papers, 23.5k citations indexed

About

Jeffrey Settleman is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Jeffrey Settleman has authored 158 papers receiving a total of 23.5k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Molecular Biology, 60 papers in Oncology and 45 papers in Cell Biology. Recurrent topics in Jeffrey Settleman's work include Protein Kinase Regulation and GTPase Signaling (48 papers), Lung Cancer Treatments and Mutations (32 papers) and Cellular Mechanics and Interactions (24 papers). Jeffrey Settleman is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (48 papers), Lung Cancer Treatments and Mutations (32 papers) and Cellular Mechanics and Interactions (24 papers). Jeffrey Settleman collaborates with scholars based in United States, France and United Kingdom. Jeffrey Settleman's co-authors include Daniel A. Haber, Daphne W. Bell, Sreenath V. Sharma, Raffaella Sordella, Jeffrey A. Engelman, Thomas J. Lynch, A. John Iafrate, Ultan McDermott, Margaret P. Quinlan and Ryan B. Corcoran and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Jeffrey Settleman

158 papers receiving 23.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidermal growth factor receptor mutations in lung cancer

2007 2.5k citations Sreenath V. Sharma, Daphne W. Bell et al. profile →
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

2009 1.5k citations Alice T. Shaw, Beow Y. Yeap et al. Journal of Clinical Oncology profile →
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

2004 1.3k citations Raffaella Sordella, Daphne W. Bell et al. Science profile →
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

2008 1.3k citations Shyamala Maheswaran, Lecia V. Sequist et al. profile →
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 774 citations Eunice L. Kwak, Raffaella Sordella et al. profile →
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

2012 767 citations Ryan B. Corcoran, Hiromichi Ebi et al. Cancer Discovery profile →
Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1

1993 760 citations Jeffrey Settleman et al. profile →
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

2008 661 citations Lecia V. Sequist, Georgiana Kuhlmann et al. Journal of Clinical Oncology profile →
SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

2011 537 citations Jeffrey Settleman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Settleman United States	72	14.0k	10.4k	7.7k	3.8k	3.7k	158	23.5k
Patricia S. Steeg United States	73	13.2k 0.9×	8.4k 0.8×	5.2k 0.7×	4.3k 1.1×	1.6k 0.4×	200	23.1k
Michael J. Eck United States	76	18.3k 1.3×	12.5k 1.2×	11.2k 1.5×	4.5k 1.2×	3.4k 0.9×	158	32.5k
Jeremy A. Squire Canada	79	18.5k 1.3×	13.3k 1.3×	8.1k 1.1×	8.6k 2.3×	2.2k 0.6×	382	33.7k
Dennis C. Sgroi United States	71	11.1k 0.8×	8.7k 0.8×	2.8k 0.4×	6.8k 1.8×	2.2k 0.6×	173	21.0k
Robert L. Sutherland Australia	78	10.4k 0.7×	7.8k 0.7×	3.3k 0.4×	3.8k 1.0×	1.3k 0.4×	236	19.2k
Michael Ittmann United States	71	13.4k 1.0×	4.6k 0.4×	6.1k 0.8×	5.1k 1.3×	1.7k 0.5×	279	20.8k
Yibin Kang United States	77	15.7k 1.1×	11.2k 1.1×	2.7k 0.3×	8.3k 2.2×	1.8k 0.5×	193	25.3k
Levi A. Garraway United States	68	14.9k 1.1×	7.0k 0.7×	3.9k 0.5×	5.6k 1.5×	1.7k 0.5×	173	22.5k
Lynda Chin United States	82	20.4k 1.5×	9.3k 0.9×	2.2k 0.3×	6.7k 1.8×	2.9k 0.8×	160	29.4k
Hiroyuki Mano Japan	66	9.4k 0.7×	8.4k 0.8×	8.5k 1.1×	4.6k 1.2×	805 0.2×	262	19.5k

Countries citing papers authored by Jeffrey Settleman

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Settleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Settleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Settleman more than expected).

Fields of papers citing papers by Jeffrey Settleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Settleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Settleman. The network helps show where Jeffrey Settleman may publish in the future.

Co-authorship network of co-authors of Jeffrey Settleman

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Settleman. A scholar is included among the top collaborators of Jeffrey Settleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Settleman. Jeffrey Settleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Apetri, Mihaela, et al.. (2015). Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors. Molecular Cancer Research. 13(4). 765–774. 19 indexed citations

Lee, Genee Y., Peter M. Haverty, Li Li, et al.. (2014). Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes. Cancer Research. 74(11). 3114–3126. 125 indexed citations

Tan, Nguyen, Michelle Nannini, Rebecca Hong, et al.. (2013). Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models. Molecular Cancer Therapeutics. 12(6). 853–864. 61 indexed citations

Corcoran, Ryan B., S. Michael Rothenberg, Aaron N. Hata, et al.. (2013). TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. Science Translational Medicine. 5(196). 196ra98–196ra98. 110 indexed citations

Wang, Meng, Liliana Gheorghiu, Patricia Greninger, et al.. (2013). EGFR-Activating Mutations Correlate with a Fanconi Anemia–like Cellular Phenotype That Includes PARP Inhibitor Sensitivity. Cancer Research. 73(20). 6254–6263. 35 indexed citations

Corcoran, Ryan B., Hiromichi Ebi, Alexa B. Turke, et al.. (2012). EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery. 2(3). 227–235. 767 indexed citations breakdown →

Wilson, Kristy J., Christopher P. Mill, Richard L. Gallo, et al.. (2012). The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. Biochemical Journal. 443(1). 133–144. 5 indexed citations

Corcoran, Ryan B., Gianmarco Contino, Vikram Deshpande, et al.. (2011). STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis. Cancer Research. 71(14). 5020–5029. 334 indexed citations

Gandhi, Leena, Kate L. McNamara, Danan Li, et al.. (2009). Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis. Cancer Prevention Research. 2(4). 330–337. 30 indexed citations

10.

Shaw, Alice T., Beow Y. Yeap, Mari Mino–Kenudson, et al.. (2009). Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK. Journal of Clinical Oncology. 27(26). 4247–4253. 1463 indexed citations breakdown →

11.

McDermott, Ultan, A. John Iafrate, Shyamala Maheswaran, et al.. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Research. 69(9). 3937–3946. 83 indexed citations

12.

Bass, Mark D., et al.. (2008). p190RhoGAP is the convergence point of adhesion signals from α5β1 integrin and syndecan-4. The Journal of Cell Biology. 181(6). 1013–1026. 92 indexed citations

13.

Montagut, Clara, Sreenath V. Sharma, Toshi Shioda, et al.. (2008). Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Research. 68(12). 4853–4861. 405 indexed citations

14.

Shen, Che-Hung, Hsin‐Yi Chen, Cheng‐Chi Chang, et al.. (2008). Breast Tumor Kinase Phosphorylates p190RhoGAP to Regulate Rho and Ras and Promote Breast Carcinoma Growth, Migration, and Invasion. Cancer Research. 68(19). 7779–7787. 72 indexed citations

15.

Quinlan, Margaret P., Steven Quatela, Mark R. Philips, & Jeffrey Settleman. (2008). Activated Kras, but Not Hras or Nras, May Initiate Tumors of Endodermal Origin via Stem Cell Expansion. Molecular and Cellular Biology. 28(8). 2659–2674. 75 indexed citations

16.

McDermott, Ultan, A. John Iafrate, Nathanael S. Gray, et al.. (2008). Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors. Cancer Research. 68(9). 3389–3395. 312 indexed citations

17.

Mulloy, Roseann, Audrey Ferrand, Young‐Joo Kim, et al.. (2007). Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib. Cancer Research. 67(5). 2325–2330. 150 indexed citations

18.

Godin-Heymann, Nadia, Miguel N. Rivera, Lindsey Ulkus, et al.. (2007). Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation. Cancer Research. 67(15). 7319–7326. 120 indexed citations

19.

Sordella, Raffaella, Daphne W. Bell, Daniel A. Haber, & Jeffrey Settleman. (2004). Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Science. 305(5687). 1163–1167. 1337 indexed citations breakdown →

20.

Zrihan‐Licht, Sheila, Yigong Fu, Jeffrey Settleman, et al.. (2000). RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene. 19(10). 1318–1328. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact